Femasys Inc is a medical instruments & supplies business based in the US. Femasys shares (FEMY) are listed on the NASDAQ and all prices are listed in US Dollars. Femasys employs 27 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.01 |
|---|---|
| 52-week range | $1.26 - $10.79 |
| 50-day moving average | $1.57 |
| 200-day moving average | $3.77 |
| Wall St. target price | $10.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.91 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.01 from 2022-07-01
| 1 week (2022-06-24) | 6.91% |
|---|---|
| 1 month (2022-06-03) | 34.00% |
| 3 months (2022-04-01) | -5.19% |
| 6 months (2022-01-03) | -49.62% |
| 1 year (2021-07-02) | -72.73% |
|---|---|
| 2 years (2020-06-29) | N/A |
| 3 years (2019-06-29) | N/A |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $1.2 million |
|---|---|
| Gross profit TTM | $809,305 |
| Return on assets TTM | -36.44% |
| Return on equity TTM | -67.98% |
| Profit margin | 0% |
| Book value | $1.99 |
| Market capitalisation | $22.2 million |
TTM: trailing 12 months
We're not expecting Femasys to pay a dividend over the next 12 months.
Femasys Inc. , a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.